by dyadic | Jul 31, 2025 | Press Releases
JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input...
by dyadic | Jul 31, 2025 | Press Releases
JUPITER, Fla., July 31, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input...
by dyadic | Jul 30, 2025 | Press Releases
JUPITER, Fla., July 30, 2025 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic” or the “Company”) (Nasdaq: DYAI), a global biotechnology company focused on the scalable production of high-value, precision engineered functional input...
by dyadic | Jul 2, 2025 | Press Releases
Reflects the Company’s strategic focus on commercializing non-therapeutic proteins and unlocking long-term value from its C1 and Dapibus™ gene expression platforms JUPITER, Fla. – Dyadic International, Inc. (“Dyadic”) (Nasdaq: DYAI), a...
by dyadic | Jun 2, 2025 | Press Releases
Rapid commercial validation has been achieved through key partnerships disrupting high value/high growth marketsLeadership team realigned in order to enable execution of ancillary protein strategyDyadic is well positioned to seize on geopolitical tailwinds driving...
